

We use cookies to personalize content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. [Cookie Policy](#)

[Cookie Settings](#)[✓ Accept Cookies](#)

Bausch Health Will Begin Trading as “BHC” on NYSE and TSX on Monday, July 16

LAVAL, Quebec, July 13, 2018 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company” or “we”) today announced the Company’s name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. is complete.

“Choosing Bausch Health as our new corporate name is very meaningful, because the Bausch name has long been a highly respected name in the health care space, synonymous for 165 years with innovation and an unwavering dedication to improving people’s lives,” said Joseph C. Papa, chairman and CEO, Bausch Health. “It is a legacy that defines us today and sets the stage for our future as we continue to transform the Company.”

Bausch Health will begin trading as “BHC” on the New York Stock Exchange and Toronto Stock Exchange on July 16, 2018.

As part of the name change, Bausch Health has unveiled a new corporate brand visual identity, and on July 16, 2018, will launch a new corporate web site: www.bauschhealth.com.

Because the Company’s businesses and subsidiaries have strong brand equity, all entities that have separate established brands will continue to operate under the corporate umbrella using their existing names.

[Read More](#)



[Go to all assets](#)

Choosing Bausch Health as our new corporate name is meaningful, because the Bausch name has long been a highly respected name in health care, synonymous for 165 years with innovation and an unwavering dedication to improving people’s lives – Joe Papa, Bausch Health CEO [Tweet](#)

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and

We use cookies to personalize content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. [Cookie Policy](#)



making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

###

Investor Contact:

Arthur Shannon
arthur.shannon@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)

Media Contact:

Lainie Keller
lainie.keller@bauschhealth.com
(908) 927-0617



Powered by MultiVu, a Cision company.

